Today, a majority of CML patients benefit from tyrosine kinase inhibitors (TKIs) which target the constitutively active BCR-ABL protein, which have brought the 5-year survival rate of CML patients above 80% [1]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.